Company
Your Cognitive Compass...
A Path to Cognitive Health and Peace of Mind
Cognivue® is the world’s first FDA-cleared test of cognitive function. Cognivue objectively, quantitatively and reliably identifies changes in cognitive function that could be indicative of an impairment that you may optimally treat or manage. It’s personalized, consistent and reliable.
The health care system tests routinely for conditions such as cervical cancer, diabetes, cholesterol, colon cancer, etc., but there is no consistent standard of care around cognitive health testing. Cognitive testing is often performed too late when cognitive functions are moderate or severely impaired. In addition, current cognitive testing consists of simple decade-old tests performed either with paper and pencil or embedded in a computer. Cognivue elevates the current standard of care as it relates to cognitive testing.
For Primary Care Providers
No referrals are necessary. Cognivue is a rapid, office-based solution for routine cognitive function monitoring.
- 10 sub-tests in 10 minutes
- 4 key domains of the brain
- Self-administered
- Reimbursable
For Patients and Family
Cognivue enables cognitive function testing, which allows for early detection and proper management. It can detect early signs cognitive decline for patients in all healthcare settings.
- Accessible testing across time and location
- Immediate results
- Single, quantitative clinical score
For Integrated Delivery Networks (IDNs) and Payers
By establishing an early clinical score, physicians are able to intervene and provide their patients with an effective treatment plan. There are many effective treatment clinical outcomes, such as:
- Treating reversible dementia
- Managing co-morbidities
- Avoiding complications, polypharmacy, and procedures
For the Industry
Cognivue provides rapid, standardized CRO cognitive function testing of new molecules.
- CogniWheel™ global patient interface
- Cloud-based results, storage, and analytics
- Primary Care Physician (PCP) engagement in testing and monitoring of new treatments
Early and accurate diagnosis leads to better disease management, patient outcomes and improved quality of life. It also can lower state and patient costs through an orderly plan for care, rather than one filled with crisis, frequent hospital visits and unanticipated expenses. Alzheimer’s can be a cruel disease. While there is yet no cure, early diagnosis and disease management can help ease the burden on patients, their families and the state budget. We urge our lawmakers to support this reasonable budget allocation.
Bruce L. Miller, professor of neurology at the University of California, San Francisco, and director of the UCSF dementia center.